Totally implantable venous-access ports: Local problems and extravasation injury

Lancet Oncology

Volumn 3, Issue 11, 2002, Pages 684-692

  Kurul, Sidika ^a   Saip, Pinar ^a   Aydin, Tulay ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CHLORMETHINE; CISPLATIN; DACARBAZINE; DACTINOMYCIN; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; IDARUBICIN; MITHRAMYCIN; MITOMYCIN C; MITOXANTRONE; NAVELBINE; PACLITAXEL; TENIPOSIDE; VINBLASTINE; VINCRISTINE; VINDESINE;

CANCER; CATHETER; CATHETER INFECTION; CONTROLLED STUDY; DRUG INFUSION; EXTRAVASATION INJURY; HEALTH CARE PERSONNEL; HISTOCOMPATIBILITY; HUMAN; IMPLANT; INJURY; LONG TERM CARE; PAIN; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; SKIN NECROSIS; SKIN ULCER; TISSUE NECROSIS; VASCULAR ACCESS; VEIN; VEIN THROMBOSIS;

EID: 0036845321     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(02)00905-1     Document Type: Review

References (66)

1. Alexander RI. Vascular access and specialized techniques of drug delivery. In: De Vita VT, Helman S, Rosenberg SA, (Eds). Cancer: principles and practice of oncology. Philadelphia: Lippincott-Raven, 1997: 725-34.
2. Whickham R, Purl S, Welker. Long-term central venous catheters: issues for care. Semin Oncol Nurs 1992; 8: 133-47.
3. Silver DF, Hempling RE, Recio FO, et al. Complications related to indwelling caval catheters on a gynecologic oncology services. Gynecol Oncol 1998; 70: 329-33.
4. Schwarz RE, Groeger J, Coit DG. Subcutaneously implanted central venous access devices in cancer patients: a prospective analysis. Cancer 1997; 79: 1635-50.
5. Biffi R, deBraud F, Orsi F, et al. Totally implantable central venous access port for long-term chemotherapy. Ann Oncol 1998; 9: 767-73.
6. Greene JN. Catheter-related complications of cancer therapy. Infect Dis Clin North Am 1996; 10: 255-95.
7. Niederhuber JE, Ensminger W, Gywes JW, et al. Totally implanted venous and arterial access system to replace external catheter in cancer treatment. Surgery 1982; 92: 706-12.
8. Puel V, Caudry M, Le Metayer P, et al. Superior vena cava thrombosis related to catheter malposition in cancer chemotherapy given through implanted ports. Cancer 1993; 72: 2248-52.
9. Kock HJ, Pietsch M, Krause U, et al. Implantable venous access system: experience in 1500 patients with totally implanted central venous port system. World J Surg 1998; 22: 12-16.
10. Lemners NWM, Gels ME, Sleijfer D, et al. Complications of venous access ports in 132 patients with disseminated testicular cancer treated with polychemotherapy. J Clin Oncol 1996; 14: 2916-22.
11. Freytes C. Indications and complications of intravenous devices for chemotherapy. Curr Opin Oncol 2000; 12: 303-07.
12. Bland KI, Woodcock T. Totally implantable venous access system for cyclic administration of cytotoxic chemotherapy. Am J Surg 1984; 147: 815-16.
13. Champault G. Totally implantable catheters for cancer chemotherapy: French experience on 325 cases. Cancer Drug Delivery 1986; 3: 131-37.
14. Gyves J, Ensminger W, Niederhuber J, et al. Totally implanted system for intravenous chemotherapy in patients with cancer. Am J Med 1982; 73: 841-45.
15. Libutti SK, Horne McDonald K. Vascular access and specialised techniques of drug delivery. In: Devita VT, Hellman S, Rosenberg S, (Eds). Cancer: principles and practice of oncology. Philadelphia: Lippincott-Raven, 2001: 760-69.
16. Bow EJ, Kilpatrick G, Clinch JJ. Totally implantable venous ports systems for patients receiving chemotherapy for solid tissue malignancies: a randomized controlled clinical trial examining the safety, efficacy, costs, and impact on quality of life. J Clin Oncol 1999; 17: 1267-73.
17. Di Carlo I, Cordio S, La Gresa G, et al. Totally implantable venous access devices implanted surgically: a retrospective study on early and late complications. Arch Surg 2001; 136: 1050-53.
18. Biffi R, De Brand F, Orsi F, et al. A randomized, prospective trial of central venous ports connected to standard open-ended or Groshong catheters in adult oncology patients. Cancer 2001; 92: 1204-12.
19. Domingo P, Fontanet A. Management of complications associated with totally implantable ports in patients with AIDS. AIDS Patient Care 2001; 15: 7-13.
20. Aitken DR, Milton JP. The "pinch-off sign": a warning of impending problems with permanent subclavian catheters. Am J Surg 1984; 148: 633-36.
21. Cathcart Rake WE, Mowery WE. Intrapericardial infusion of 5-fluorouracil: an unusual complication of a Hickman catheter. Cancer 1991; 67: 735-37.
22. Rodier JM, Malbec L, Lauraine EP, et al. Mediastinal infusion of epirubicin and 5-fluorouracil: a complication of totally implantable central venous systems. J Cancer Res Clin Oncol 1996; 122: 566-67.
23. Laffer U, Dürig M, Bloch HR, Landman J. Surgical experiences with 191 implanted venous Port-a-Cath systems. Rec Results Cancer Res 1991; 121: 189-97.
24. Nanninga AG, deVries EGE, Willemsw PHB, et al. Continuous infusion of chemotherapy on an outpatient basis via a totally implanted venous access port. Eur J Cancer 1991; 27: 147-49.
25. Strum S, McDermed J, Korn A, Joseph C. Improved methods for venous access: the Port-a-Cath, a totally implanted system. J Clin Oncol 1986; 4: 596-603.
26. Hsiung GR, Swanson PD. Cerebral air embolism after central venous catheter removal. Neurology 2000; 55: 1063-64.
27. Müller M, Ziersky J. Die Huber Nadel als Spezialkanüle für die Punktion von implantierten Ports und Pumpen-ein Irrtum in Zahlreichen Variationen. Klin Wochenschr 1998; 66: 963-69.
28. Haindl H, Müller H. Eine atrauvmatische Nadel für die Punktion von Ports und Pumpen. Klin Wochenschr 1998; 66:1006-09.
29. Haindl H. Technical complications of port-catheter systems. Reg Cancer Treat 1989; 2: 238-42.
30. Gyves J, Ensminger W, Niederhuber J, et al. A totally implanted injection port system for blood sampling and chemotherapy administration. JAMA 1984; 251: 2538-41.
31. Haire WD, Lieberman RP, Edney J, et al. Hickman catheter-induced thoracic vein thrombosis. Cancer 1990; 66: 900-08.
32. Hallquist P. Extravasation of infusate via implanted ports: two case studies. Clin J Oncol Nurs 1999; 3: 145-51.
33. Howard L, Claunch C, McDowell R, Timchalk M. Five years experience in patients receiving home nutrition support with implanted reservoir: a comparison with the external catheter. J Parenter Enteral Nutr 1989; 13: 478-83.
34. Yung B, Elborn JS, Campbell IA, et al. Thromboembolism related to a Port-a-Cath device in a patient with cystic fibrosis. Thorax 1997; 52: 98-99.
35. Klotz HP, Schöpke W, Kohler A, et al. Catheter fracture: a rare complication of totally implantable subclavian venous access devices. J Surg Oncol 1996; 62: 222-25.
36. Di Carlo I, Fisichella P, Russello D, et al. Catheter fracture and cardiac migration: a rare complication of totally implantable venous access devices. J Surg Oncol 2000; 73: 172-73.
37. Wai-Chi Lam A, Chen Y, Yang K, et al. Disconnection of a venous Port-A-Cath followed by embolization after saline flush: rare case report. J Clin Oncol 1999; 29: 643-45.
38. Martin AJ, Morris LL, Reece J, et al. Totally implantable vascular access in treatment of cystic fibrosis. Lancet 1986; 1: 293.
39. Mueller BU, Skelton J, Callender DPE, et al. A prospective randomized trial comparing the infectious and non-infectious complications of an exteralized catheter versus a subcutaneously implanted device in cancer patients. J Clin Oncol 1992; 10: 1943-48.
40. Nesti SP, Kovac R. 5-fluorouracil extravasation following port failure. J Intraven Nurs 2000; 23: 176-80.
41. Albanell J, Baselga J. Systemic therapy emergencies. Semin Oncol 2000; 27: 347-60.
42. Shenaq SM, Abbase EA, Friedman JD. Soft-tissue reconstruction following extravasation of chemotherapeutic agents. Surg Ontol Clin North Am 1996; 5: 825-45.
43. Disa JJ, Chang RR, Mucci SJ, Goldberg NH. Prevention of adriamycin-induced full-thickness skin loss using hyaluronidase infiltration. Plast Reconstr Surg 1998; 101: 370-74.
44. Gault DT. Extravasation injures. Br J Plast Surg 1993; 46: 91-96.
45. Rudolph R, Larson L. Etiology and treatment of chemotherapeutic agent extravasation injuries: a review. J Clin Oncol 1987; 5: 1116-26.
46. Larson DL. What is the appropriate management of tissue extravasation by antitumor agents? Plast Reconstr Surg 1983; 75: 397-402.
47. Larson DL. Alterations in wound healing secondary to infusion injury. Clin Plast Surg 1990; 17: 509-17.
48. Ajani JA, Dodd LG, Daugherty K, et al. Taxol-induced soft tissue injury secondary to extravasation: characterization by histopathology and clinical course. J Natl Cancer Inst 1994; 86: 51-53.
49. Bairey O, Bishara. J, Stahl B, Shaklai M. Severe tissue necrosis after cisplatin extravasation at low concentration: possible "immediate recall phenomenon". J Natl Cancer Inst 1997; 89: 1233-34.
50. Madhavan S, Northfelt DW. Lack of vesicant injury following extravasation of liposomal doxorubicin. J Natl Cancer Inst 1995; 87: 1556-57.
51. Raley J, Geisler J, Buckets TE, Sorosky JI. Docetaxel extravasation causing significant delayed tissue injury. Gynecol Oncol 2000; 78: 259-60.
52. Meehan JL, Sporn JR. Case report of taxol administration via central vein producing a recall reaction at a site of prior taxol extravasation. J Natl Cancer Inst 1994; 86: 1250-51.
53. Yama N, Tsuchida Y, Nuka S, et al. Usefulness of magnetic resonance imaging for surgical management of extravasation of an antitumor agents: a case report. J Clin Oncol 2001; 31: 122-24.
54. Ascherman JA, Knowles SL, Attkiss K. Docetaxel (Taxotere) extravasation: a report of five cases with treatment recommendation. Ann Plast Surg 2000; 45: 439-41.
55. Schwartsman G, Sander EB, Vinholes J, Sanvitto G. N-acetylcystein protects skin lesion induced by local extravasation of doxorubicin in a rat model. Am J Pediatr Hematol Oncol 1992; 14: 280-81.
56. Langer SW, Sehested M, Jensen PB. Dexrazoxane in anthracycline extravasation. J Clin Oncol 2000; 18: 3064.
57. Ranwijck R. Liposuction to radiologist's rescue. Plast Reconstr Surg 1993; 92: 175-76.
58. Harris PA, Bradley S, Moss AH. Limiting the damage of iatrogenic extravasation injury in neonates. Plast Reconst Surg 2001; 107: 893-94.
59. Vandeweyer E, Heymans O, Deraemaecker R. Extravasation injuries and emergency suction as treatment. Plast Reconstr Surg 2000; 105 109-10.
60. Uzunismail A, Kurul S, Elbüken E, et al. Utility of hyperbaric oxygen (HBO) treatment in cytostatic extravasation: an experimental study. Turkish J Oncol 1993; 8: 1283-88.
61. Monstrey SJ, Mullick P, Narayanan K, Ramasastry SS. Hyperbaric oxygen therapy and free radical production: an experimental study in doxorubicin (adriamycin) extravasation injuries. Ann Plast Surg 1997; 38: 163-68.
62. Aktas S, Toklu AS, Olgac V. Hyperbaric oxygen therapy in adriamycin extravasation: an experimental animal study. Ann Plast Surg 2000; 45: 167-71.
63. Kurul S. Use of homograft skin in chronic cytostatic extravasation injury as a biological dressing. Reg Chemother 1994; 7: 170-71.
64. Matos M, Cruz NI. Reversing detrimental effect of Adriamicin on skin graft in rats. Plast Reconstr Surg 1987; 80: 591-94.
65. Devereux DF, Thibault L, Boretos J, Brennan MF. The quantitative and qualitative impairment of wound healing by adriamicin. Cancer 1979; 43: 932-37.
66. Kurul S, Uzunismail A, Elbuken E, et al. Effect of hyperbaric oxygen therapy on compromised skin flap survival due to systemic chemotherapy (adriamycin) in rats: an experimental study. Turkish J Med Biol Res 1993; 4: 197-209.